SphingoTec develops and markets innovative in vitro diagnostics solutions for novel and proprietary blood-based protein biomarkers. Our aspiration is to effectively translate scientific advancements into routine clinical practice.
Our innovative biomarkers address diagnostically underserved critical care conditions such as sepsis, acute heart failure, acute kidney injury, and cardiogenic shock.
We are a fully integrated diagnostics company: our innovative biomarkers are commercially available on the point of care platform Nexus IB10. The assay portfolio for near patient testing goes beyond innovation: on the Nexus IB10 platform, clinicians can deploy a wide range of commonly used parameters in acute and critical care settings, making the analyzer a useful addition to intensive care units (ICU), emergency departments (ED), and other near patient settings.